Lonafarnib (SCH66336) improves the activity of temozolomide and radiation for orthotopic malignant gliomas

Journal of Neuro-Oncology

Volumn 104, Issue 1, 2011, Pages 179-189

  Chaponis, Deviney ^a   Barnes, Jessica W ^a   Dellagatta, Jamie L ^a   Kesari, Santosh ^b   Fast, Eva ^b   Sauvageot, Claire ^b   Panagrahy, Dipak ^a   Greene, Emily R ^a   Ramakrishna, Naren ^b,c   Wen, Patrick Y ^b,c   Kung, Andrew L ^a   Stiles, Charles ^b   Kieran, Mark W ^a,b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Farnesyltransferase inhibitor; Orthotopic glioma; Radiation therapy; Ras; Stem cell; Temozolomide

Indexed keywords

H RAS PROTEIN; LONAFARNIB; RAS PROTEIN; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER SIZE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MONOTHERAPY; MOUSE; NONHUMAN; PROTEIN MODIFICATION; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DACARBAZINE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; GLIOMA; HUMANS; MICE; NEOPLASM TRANSPLANTATION; PIPERIDINES; PRENYLATION; PYRIDINES; RADIATION, IONIZING; RAS PROTEINS; SIGNAL TRANSDUCTION; TIME FACTORS;

EID: 80052710752     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-010-0502-4     Document Type: Article

References (51)

1. CB Scott C Scarantino R Urtasun B Movsas CU Jones JR Simpson AJ Fischbach WJ Curran Jr 1998 Validation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant glioma patients: a report using RTOG 90-06 Int J Radiat Oncol Biol Phys 40 51 55 9422557 10.1016/S0360-3016(97)00485-9 1:STN:280:DyaK1c%2FotlShsg%3D%3D (Pubitemid 28027566)
2. R Stupp PY Dietrich S Ostermann Kraljevic A Pica I Maillard P Maeder R Meuli R Janzer G Pizzolato R Miralbell F Porchet L Regli N de Tribolet RO Mirimanoff S Leyvraz 2002 Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide J Clin Oncol 20 1375 1382 11870182 10.1200/JCO.20.5.1375 1:CAS:528:DC%2BD38XisVWmu7s%3D (Pubitemid 34177445)
3. MK Nicholas 2007 Glioblastoma multiforme: evidence-based approach to therapy Expert Rev Anticancer Ther 7 S23 S27 18076314 10.1586/14737140.7.12s.S23 1:CAS:528:DC%2BD2sXhsVWgs7zJ
4. ML Falchetti MP Mongiardi P Fiorenzo G Petrucci F Pierconti I D'Agnano G D'Alessandris G Alessandri M Gelati L Ricci-Vitiani G Maira LM Larocca A Levi R Pallini 2008 Inhibition of telomerase in the endothelial cells disrupts tumor angiogenesis in glioblastoma xenografts Int J Cancer 122 1236 1242 18027853 10.1002/ijc.23193 1:CAS:528:DC%2BD1cXit1yhs7w%3D (Pubitemid 351287222)
5. ML Falchetti P Fiorenzo MP Mongiardi G Petrucci N Montano G Maira F Pierconti LM Larocca A Levi R Pallini 2006 Telomerase inhibition impairs tumor growth in glioblastoma xenografts Neurol Res 28 532 537 16808885 10.1179/016164106X116818 1:CAS:528:DC%2BD28Xos12jt7k%3D (Pubitemid 44141323)
6. C Belda-Iniesta J de Castro Carpeno M Sereno M Gonzalez-Baron R Perona 2008 Epidermal growth factor receptor and glioblastoma multiforme: molecular basis for a new approach Clin Transl Oncol 10 73 77 18258505 10.1007/s12094-008-0159-z 1:CAS:528:DC%2BD1cXjsl2js7k%3D
7. H Ohgaki P Kleihues 2007 Genetic pathways to primary and secondary glioblastoma Am J Pathol 170 1445 1453 17456751 10.2353/ajpath.2007.070011 1:CAS:528:DC%2BD2sXlvFCns74%3D (Pubitemid 47339290)
8. C Sarkar AK Karak N Nath MC Sharma AK Mahapatra P Chattopadhyay S Sinha 2005 Apoptosis and proliferation: correlation with p53 in astrocytic tumours J Neurooncol 73 93 100 15981097 10.1007/s11060-004-3015-1 1:CAS:528: DC%2BD2MXhtlSgsL%2FM (Pubitemid 40974028)
9. WR Voelzke WJ Petty GJ Lesser 2008 Targeting the epidermal growth factor receptor in high-grade astrocytomas Curr Treat Options Oncol 9 23 31 18247132 10.1007/s11864-008-0053-5
10. M Failly S Korur V Egler JL Boulay MM Lino R Imber A Merlo 2007 Combination of sublethal concentrations of epidermal growth factor receptor inhibitor and microtubule stabilizer induces apoptosis of glioblastoma cells Mol Cancer Ther 6 773 781 17308073 10.1158/1535-7163.MCT-06-0566 1:CAS:528:DC%2BD2sXhvVWrtb8%3D (Pubitemid 46332478)
11. CB Knobbe J Reifenberger G Reifenberger 2004 Mutation analysis of the Ras pathway genes NRAS, HRAS, KRAS and BRAF in glioblastomas Acta Neuropathol 108 467 470 15517309 10.1007/s00401-004-0929-9 1:CAS:528:DC%2BD2cXhtVSitLrK (Pubitemid 39534587)
12. MM Feldkamp P Lala N Lau L Roncari A Guha 1999 Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens Neurosurgery 45 1442 1453 10598712 10.1097/00006123-199912000-00034 1:STN:280:DC%2BD3c%2FmsFOksw%3D%3D
13. BC Widemann WL Salzer RJ Arceci SM Blaney E Fox D End A Gillespie P Whitcomb JS Palumbo A Pitney N Jayaprakash P Zannikos FM Balis 2006 Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas J Clin Oncol 24 507 516 16421428 10.1200/JCO.2005.03. 8638 1:CAS:528:DC%2BD28XhsFSrsr8%3D (Pubitemid 46630471)
14. DA Haas-Kogan A Banerjee M Kocak MD Prados JR Geyer M Fouladi T McKnight TY Poussaint A Broniscer SM Blaney JM Boyett LE Kun 2008 Phase I trial of tipifarnib in children with newly diagnosed intrinsic diffuse brainstem glioma Neuro Oncol 10 341 347 18417739 10.1215/15228517-2008-004 1:CAS:528: DC%2BD1cXoslOrsbY%3D
15. MW Kieran RJ Packer A Onar SM Blaney P Phillips IF Pollack JR Geyer S Gururangan A Banerjee S Goldman CD Turner JB Belasco A Broniscer Y Zhu E Frank P Kirschmeier P Statkevich A Yver JM Boyett LE Kun 2007 Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a Pediatric Brain Tumor Consortium Study J Clin Oncol 25 3137 3143 17634493 10.1200/JCO.2006.09. 4243 1:CAS:528:DC%2BD2sXptlGrt70%3D (Pubitemid 47218063)
16. F Morgillo HY Lee 2006 Lonafarnib in cancer therapy Expert Opin Invest Drugs 15 709 719 10.1517/13543784.15.6.709 1:CAS:528:DC%2BD28XltVOgsb8%3D
17. EJ Bernhard WG McKenna AD Hamilton SM Sebti Y Qian JM Wu RJ Muschel 1998 Inhibiting Ras prenylation increases the radiosensitivity of human tumor cell lines with activating mutations of Ras oncogenes Cancer Res 58 1754 1761 9563495 1:CAS:528:DyaK1cXisleru7w%3D (Pubitemid 28215105)
18. CC Ling B Endlich 1989 Radioresistance induced by oncogenic transformation Radiat Res 120 267 279 2694214 10.2307/3577713 1:CAS:528:DyaL1MXlvFSnsLs%3D (Pubitemid 19275183)
19. WG McKenna MC Weiss VJ Bakanauskas H Sandler ML Kelsten J Biaglow SW Tuttle B Endlich CC Ling RJ Muschel 1990 The role of the H-Ras oncogene in radiation resistance and metastasis Int J Radiat Oncol Biol Phys 18 849 859 2182580 10.1016/0360-3016(90)90407-B 1:CAS:528:DyaK3cXksleku7o%3D (Pubitemid 20154043)
20. AC Miller J Gafner EP Clark D Samid 1993 Differences in radiation-induced micronuclei yields of human cells: influence of Ras gene expression and protein localization Int J Radiat Biol 64 547 554 7902394 10.1080/09553009314551761 1:CAS:528:DyaK2cXkvFShtA%3D%3D (Pubitemid 23350456)
21. AK Gupta VJ Bakanauskas WG McKenna EJ Bernhard RJ Muschel 2001 Ras regulation of radioresistance in cell culture Methods Enzymol 333 284 290 11400344 10.1016/S0076-6879(01)33063-X 1:CAS:528:DC%2BD3MXltV2nurc%3D (Pubitemid 32507316)
22. TL Glass TJ Liu WK Yung 2000 Inhibition of cell growth in human glioblastoma cell lines by farnesyltransferase inhibitor SCH66336 Neuro-Oncol 2 151 158 11302335 1:STN:280:DC%2BD3M3jsF2hug%3D%3D
23. O Szentirmai CH Baker N Lin S Szucs M Takahashi S Kiryu AL Kung RC Mulligan BS Carter 2006 Noninvasive bioluminescence imaging of luciferase expressing intracranial U87 xenografts: correlation with magnetic resonance imaging determined tumor volume and longitudinal use in assessing tumor growth and antiangiogenic treatment effect Neurosurgery 58 365 372 16462491 10.1227/01.NEU.0000195114.24819.4F (discussion 365-372) (Pubitemid 43212802)
24. JB Rubin AL Kung RS Klein JA Chan Y Sun K Schmidt MW Kieran AD Luster RA Segal 2003 A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors Proc Natl Acad Sci USA 100 13513 13518 14595012 10.1073/pnas.2235846100 1:CAS:528:DC%2BD3sXptFOit78%3D (Pubitemid 37444773)
25. KL Ligon E Huillard S Mehta S Kesari H Liu JA Alberta RM Bachoo M Kane DN Louis RA Depinho DJ Anderson CD Stiles DH Rowitch 2007 Olig2-regulated lineage-restricted pathway controls replication competence in neural stem cells and malignant glioma Neuron 53 503 517 17296553 10.1016/j.neuron.2007.01.009 1:CAS:528:DC%2BD2sXis1altLk%3D (Pubitemid 46216748)
26. SK Singh ID Clarke M Terasaki VE Bonn C Hawkins J Squire PB Dirks 2003 Identification of a cancer stem cell in human brain tumors Cancer Res 63 5821 5828 14522905 1:CAS:528:DC%2BD3sXnvVSjtbc%3D (Pubitemid 37187480)
27. RR Desrosiers MH Cusson S Turcotte R Beliveau 2005 Farnesyltransferase inhibitor SCH-66336 downregulates secretion of matrix proteinases and inhibits carcinoma cell migration Int J Cancer 114 702 712 15609318 10.1002/ijc.20807 1:CAS:528:DC%2BD2MXitl2qur8%3D (Pubitemid 40344431)
28. DR Laks M Masterman-Smith K Visnyei B Angenieux NM Orozco I Foran WH Yong HV Vinters LM Liau JA Lazareff PS Mischel TF Cloughesy S Horvath HI Kornblum 2009 Neurosphere formation is an independent predictor of clinical outcome in malignant glioma Stem Cells 27 980 987 19353526 10.1002/stem.15
29. A Dowlati A Kluge D Nethery B Halmos JA Kern 2008 SCH66336, inhibitor of protein farnesylation, blocks signal transducer and activators of transcription 3 signaling in lung cancer and interacts with a small molecule inhibitor of epidermal growth factor receptor/human epidermal growth factor receptor 2 Anticancer Drugs 19 9 16 18043125 10.1097/CAD.0b013e3282f1a908 1:CAS:528:DC%2BD2sXhtlCrur%2FF (Pubitemid 350190963)
30. MM Feldkamp N Lau A Guha 1999 Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects Oncogene 18 7514 7526 10602510 10.1038/sj.onc.1203105 1:CAS:528:DC%2BD3cXpslah (Pubitemid 30035052)
31. L Sepp-Lorenzino Z Ma E Rands NE Kohl JB Gibbs A Oliff N Rosen 1995 A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines Cancer Res 55 5302 5309 7585592 1:CAS:528:DyaK2MXpsVaqsr0%3D
32. IF Pollack M Bredel M Erff AD Hamilton SM Sebti 1999 Inhibition of Ras and related guanosine triphosphate-dependent proteins as a therapeutic strategy for blocking malignant glioma growth: II-preclinical studies in a nude mouse model Neurosurgery 45 1208 1214 10549939 10.1097/00006123-199911000-00039 1:STN:280:DC%2BD3c%2Fhs1WgsA%3D%3D (discussion 1214-1205) (Pubitemid 29517527)
33. M Liu WR Bishop LL Nielsen MS Bryant P Kirschmeier 2001 Orally bioavailable farnesyltransferase inhibitors as anticancer agents in transgenic and xenograft models Methods Enzymol 333 306 318 11400347 10.1016/S0076-6879(01) 33065-3 1:CAS:528:DC%2BD3MXltV2nu78%3D (Pubitemid 32507318)
34. Y Shi J Wu R Mick GJ Cerniglia E Cohen-Jonathan JS Rhim CJ Koch EJ Bernhard 2005 Farnesyltransferase inhibitor effects on prostate tumor micro-environment and radiation survival Prostate 62 69 82 15389805 10.1002/pros.20122 1:CAS:528:DC%2BD2MXjvFyitg%3D%3D (Pubitemid 39614296)
35. R Lustig T Mikkelsen G Lesser S Grossman X Ye S Desideri J Fisher J Wright 2008 Phase II preradiation R115777 (tipifarnib) in newly diagnosed GBM with residual enhancing disease Neuro Oncol 10 1004 1009 18725460 10.1215/15228517-2008-070 1:CAS:528:DC%2BD1MXmvV2htQ%3D%3D
36. M Loprevite RE Favoni A De Cupis T Scolaro C Semino P Mazzanti A Ardizzoni 2004 In vitro study of farnesyltransferase inhibitor SCH 66336, in combination with chemotherapy and radiation, in non-small cell lung cancer cell lines Oncol Rep 11 407 414 14719076 1:CAS:528:DC%2BD2cXhsVGks7k%3D
37. EC Lerner Y Qian MA Blaskovich RD Fossum A Vogt J Sun AD Cox CJ Der AD Hamilton SM Sebti 1995 Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras-Raf complexes J Biol Chem 270 26802 26806 7592920 10.1074/jbc.270.45.26802 1:CAS:528:DyaK2MXpsVGlsr8%3D (Pubitemid 3007240)
38. A Chakravarti A Chakladar MA Delaney DE Latham JS Loeffler 2002 The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a RAS-dependent manner Cancer Res 62 4307 4315 12154034 1:CAS:528: DC%2BD38XlvFeltbY%3D (Pubitemid 34827287)
39. R Abounader S Ranganathan BY Kim C Nichols J Laterra 2001 Signaling pathways in the induction of c-met receptor expression by its ligand scatter factor/hepatocyte growth factor in human glioblastoma J Neurochem 76 1497 1508 11238734 10.1046/j.1471-4159.2001.00158.x 1:CAS:528:DC%2BD3MXhvVCjurs%3D (Pubitemid 32198254)
40. S Elowe SJ Holland S Kulkarni T Pawson 2001 Downregulation of the Ras-mitogen-activated protein kinase pathway by the EphB2 receptor tyrosine kinase is required for ephrin-induced neurite retraction Mol Cell Biol 21 7429 7441 11585923 10.1128/MCB.21.21.7429-7441.2001 1:CAS:528:DC%2BD3MXns1WjtLY%3D (Pubitemid 32953493)
41. SJ Holland NW Gale GD Gish RA Roth Z Songyang LC Cantley M Henkemeyer GD Yancopoulos T Pawson 1997 Juxtamembrane tyrosine residues couple the Eph family receptor EphB2/Nuk to specific SH2 domain proteins in neuronal cells EMBO J 16 3877 3888 9233798 10.1093/emboj/16.13.3877 1:CAS:528:DyaK2sXkslShurg%3D (Pubitemid 27281004)
42. J Tong S Elowe P Nash T Pawson 2003 Manipulation of EphB2 regulatory motifs and SH2 binding sites switches MAPK signaling and biological activity J Biol Chem 278 6111 6119 12486127 10.1074/jbc.M208972200 1:CAS:528: DC%2BD3sXht1aqtbk%3D (Pubitemid 36800863)
43. I Kim YS Ryu HJ Kwak SY Ahn JL Oh GD Yancopoulos NW Gale GY Koh 2002 EphB ligand, ephrinB2, suppresses the VEGF- and angiopoietin 1-induced Ras/mitogen-activated protein kinase pathway in venous endothelial cells FASEB J 16 1126 1128 12039842 1:CAS:528:DC%2BD38XltlChu7w%3D
44. RL Klemke S Cai AL Giannini PJ Gallagher P de Lanerolle DA Cheresh 1997 Regulation of cell motility by mitogen-activated protein kinase J Cell Biol 137 481 492 9128257 10.1083/jcb.137.2.481 1:CAS:528:DyaK2sXislCht74%3D (Pubitemid 27181299)
45. AN Scott C Hetheridge AR Reynolds V Nayak K Hodivala-Dilke H Mellor 2008 Farnesyltransferase inhibitors target multiple endothelial cell functions in angiogenesis Angiogenesis 11 337 346 18758974 10.1007/s10456-008-9115-3 1:CAS:528:DC%2BD1MXivFCgsw%3D%3D
46. AD Basso A Mirza G Liu BJ Long WR Bishop P Kirschmeier 2005 The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling Role in FTI enhancement of taxane and tamoxifen anti-tumor activity J Biol Chem 280 31101 31108 16006564 10.1074/jbc.M503763200 1:CAS:528:DC%2BD2MXpsVCmtbs%3D (Pubitemid 41291845)
47. SM Sebti AD Hamilton 2000 Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies Oncogene 19 6584 6593 11426643 10.1038/sj.onc.1204146 1:CAS:528:DC%2BD3MXhsF2rsr4%3D (Pubitemid 32197696)
48. DB Whyte P Kirschmeier TN Hockenberry I Nunez-Oliva L James JJ Catino WR Bishop JK Pai 1997 K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors J Biol Chem 272 14459 14464 9162087 10.1074/jbc.272.22.14459 1:CAS:528:DyaK2sXjsFygs74%3D (Pubitemid 27232866)
49. C Lu A Shervington 2008 Chemoresistance in gliomas Mol Cell Biochem 312 71 80 18259841 10.1007/s11010-008-9722-8 1:CAS:528:DC%2BD1cXkvVOhsbs%3D
50. JN Rich 2007 Cancer stem cells in radiation resistance Cancer Res 67 8980 8984 17908997 10.1158/0008-5472.CAN-07-0895 1:CAS:528:DC%2BD2sXhtFSntbfP (Pubitemid 47535877)
51. CM Sauvageot S Kesari CD Stiles 2007 Molecular pathogenesis of adult brain tumors and the role of stem cells Neurol Clin 25 891 924 17964020 10.1016/j.ncl.2007.07.014 (vii) (Pubitemid 47600578)